In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
1. We evaluated potential in vitro drug interactions of luseogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, mediated by CYP inhibition, CYP induction and drug transporters using human liver microsomes, primary hepatocytes and recombinant cells-expressing efflux or uptake transporters, respectively. 2. Human CYP inhibition studies indicated that luseogliflozin was a weak inhibitor for CYP2C19 with an IC50value of 58.3 μM, whereas it was not an inhibitor of the other eight major isoforms that were tested. The exposure of primary hepatocytes to luseogliflozin for 72 hrs weakly induced CYP3A4 at a concentration of 10 μM, whereas it did not induce CYP1A2 or CYP2B6 at concentrations of 0.1-10 μM. 3. An in vitro transport study suggested that luseogliflozin is a substrate for human P-glycoprotein (P-gp), but not for breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1 and OATP1B3, organic anion transporter (OAT) 1 and OAT3, or organic cation transporter (OCT) 2. Luseogliflozin weakly inhibited OATP1B3 with an IC50value of 93.1 μM, but those for other transporters are greater than 100 μM. 4. Based on the therapeutic plasma concentration of the drug, clinically relevant drug interactions are unlikely to occur between luseogliflozin and coadministered drugs mediated by CYPs and/or transporters.
a Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd. , Saitama , Japan and.
Yukihiro
Y
Chino
a Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd. , Saitama , Japan and.
Masatoshi
M
Hasegawa
a Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd. , Saitama , Japan and.
Yoshiki
Y
Fukasawa
a Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd. , Saitama , Japan and.
Yoko
Y
Mano
a Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd. , Saitama , Japan and.
Kagumi
K
Bando
a Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd. , Saitama , Japan and.
Atsunori
A
Miyata
b Development Headquarters, Taisho Pharmaceutical Co., Ltd. , Tokyo , Japan.
Yasuhiro
Y
Nakai
a Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd. , Saitama , Japan and.
Hiromi
H
Endo
a Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd. , Saitama , Japan and.
Jun-Ichi
JI
Yamaguchi
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D018528:ATP-Binding Cassette Transporters; D000818:Animals; D001692:Biological Transport; D018938:Caco-2 Cells; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004285:Dogs; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D022781:Hepatocytes; D006801:Humans; D027381:Liver-Specific Organic Anion Transporter 1 / Q000378:metabolism; D061985:Madin Darby Canine Kidney Cells; D026901:Membrane Transport Proteins / Q000378:metabolism; D008862:Microsomes, Liver; D009363:Neoplasm Proteins; D027361:Organic Anion Transporters / Q000378:metabolism; D029362:Organic Anion Transporters, Sodium-Independent; D013012:Sorbitol / Q000031:analogs & derivatives* / Q000494:pharmacology
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D018528:ATP-Binding Cassette Transporters; D004791:Enzyme Inhibitors; D027381:Liver-Specific Organic Anion Transporter 1; D026901:Membrane Transport Proteins; D009363:Neoplasm Proteins; D027361:Organic Anion Transporters; D029362:Organic Anion Transporters, Sodium-Independent; C503999:SLCO1B1 protein, human; D013012:Sorbitol; D003577:Cytochrome P-450 Enzyme System; C549343:1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol
CYP; SGLT2 inhibitor; diabetes mellitus; induction; inhibition; transporter